Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier - Towards a mechanistic ivive-based approach

AAPS Journal

Volumn 15, Issue 4, 2013, Pages 913-932

  Ball, Kathryn ^a   Bouzom, François ^a   Scherrmann, Jean Michel ^b,c   Walther, Bernard ^a   Declèves, Xavier ^b,c  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

blood brain barrier; central nervous system; in vitro in vivo extrapolation; PBPK; pharmacokinetics

Indexed keywords

ATOMOXETINE; CLOZAPINE; DULOXETINE; GABAPENTIN; LOPERAMIDE; MORPHINE; OXYCODONE; PARACETAMOL; XENOBIOTIC AGENT; ZIDOVUDINE;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; DIALYSATE LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICRODIALYSIS; NONHUMAN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; REVIEW; SENSITIVITY ANALYSIS;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 84888001868     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9496-0     Document Type: Review

References (135)

1. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx. 2005;2:554-71.
2. Feher M, Sourial E, Schmidt JM. A simple model for the prediction of blood-brain partitioning. Int J Pharm. 2000;201:239-47.
3. Vilar S, Chakrabarti M, Costanzi S. Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. J Mol Graph Model. 2010;28:899-903.
4. Platts JA, Abraham MH, Zhao YH, Hersey A, Ijaz L, Butina D. Correlation and prediction of a large blood-brain distribution data set - an LFER study. Eur J Med Chem. 2001;36:719-30.
5. Pardridge WM. Log(BB), PS products and in silico models of drug brain penetration. Drug Discov Today. 2004;9:392-3.
6. Boriss H. Brain availability is the key parameter for optimising the permeability of central nervous system drugs. Drug Discov. 2010;7:57-60.
7. Jeffrey P, Summerfield S. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol Dis. 2010;37:33-7.
8. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9:929-39.
9. Fridén M, Winiwarter S, Jerndal G, Bengtsson O, Wan H, Bredberg U, et al. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem. 2009;52:6233-43.
10. Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos. 2004;32:132-9.
11. Espié P, Tytgat D, Sargentini-Maier M-L, Poggesi I, Watelet J-B. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev. 2009;41:391-407.
12. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13-25.
13. Palmer AM, Alavijeh MS. Translational CNS medicines research. Drug Discov Today. 2012;17:1068-78.
14. Deo AK, Theil F-P, Nicolas J-M. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Mol Pharm. 2013. doi: 10.1021/mp300570z.
15. Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39:711-23.
16. Reichel A. The role of blood-brain barrier studies in the pharmaceutical industry. Curr Drug Metab. 2006;7:183-203.
17. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev. 2004;56:1825-57.
18. De Lange ECM, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet. 2002;41:691-703.
19. Lin JH. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab. 2008;9:46-59.
20. Westerhout J, Danhof M, De Lange ECM. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. J Pharm Sci. 2011;100:3577-93.
21. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, et al. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos. 2006;34:1443-7.
22. De Lange ECM. Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. 2013. doi: 10.1007/s10928-013-9301-9.
23. Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a. J Pharmacol Exp Ther. 2011;339:935-44.
24. Xiao G, Black C, Hetu G, Sands E, Wang J, Caputo R, et al. Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates. Drug Metab Dispos. 2012;40:779-87.
25. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of "bottom-up" vs "top-down" recognition. Drug Metab Pharmacokinet. 2009;24:53-75.
26. Fenstermacher JD, Blasberg RG, Patlak CS. Methods for quantifying the transport of drugs across brain barrier systems. Pharmacol Ther. 1981;14:217-48.
27. Blasberg RG, Patlak CS, Shapiro WR. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep. 1977;61:633-41.
28. Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol. 1978;235:H299-307.
29. Rapoport SI, Ohno K, Pettigrew KD. Drug entry into the brain. Brain Res. 1979;172:354-9.
30. Collins JM, Dedrick RL. Distributed model for drug delivery to CSF and brain tissue. Am J Physiol. 1983;245:R303-10.
31. Deguchi Y. Application of in vivo brain microdialysis to the study of blood-brain barrier transport of drugs. Drug Metab Pharmacokinet. 2002;17:395-407.
32. Hammarlund-Udenaes M, Paalzow LK, De Lange EC. Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method. Pharm Res. 1997;14:128-34.
33. Wang Y, Welty DF. The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis- pharmacokinetic approach. Pharm Res. 1996;13:398-403.
34. Wang Y, Sawchuk RJ. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci. 1995;84:871-6.
35. Wang Y, Wei Y, Sawchuk RJ. Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. J Pharm Sci. 1997;86:1484-90.
36. Suzuki H, Terasaki T, Sugiyama Y. Role of efflux transport across the blood-brain barrier and blood-cerebrospinal fluid barrier on the disposition of xenobiotics in the central nervous system. Adv Drug Deliv Rev. 1997;25:257-85.
37. Tunblad K, Hammarlund-Udenaes M, Jonsson EN. An integrated model for the analysis of pharmacokinetic data from microdialysis experiments. Pharm Res. 2004;21:1698-707.
38. De Lange ECM, Ravenstijn PGM, Groenendaal D, Van Steeg TJ. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic- pharmacodynamic modeling. AAPS J. 2005;7:E532-43.
39. Bouw MR, Gårdmark M, Hammarlund-Udenaes M. Pharmacokinetic- pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats-A microdialysis study. Pharm Res. 2000;17:1220-7.
40. Xie R, Bouw MR, Hammarlund-Udenaes M. Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. Br J Pharmacol. 2000;131:1784-92.
41. Bouw MR, Xie R, Tunblad K, Hammarlund-Udenaes M. Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats-pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol. 2001;134:1796-804.
42. Boström E, Simonsson USH, Hammarlund-Udenaes M. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab Dispos. 2006;34:1624-31.
43. Boström E, Hammarlund-Udenaes M, Simonsson USH. Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology. 2008;108:495-505.
44. Cremers TIFH, Flik G, Hofland C, Stratford RE. Microdialysis evaluation of clozapine and N-desmethylclozapine pharmacokinetics in rat brain. Drug Metab Dispos. 2012;40:1909-16.
45. Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25:1737-50.
46. Geldof M, Freijer J, Van Beijsterveldt L, Danhof M. Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. Pharm Res. 2008;25:792-804.
47. Syvänen S, Schenke M, Van den Berg D-J, Voskuyl RA, De Lange EC. Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry-A study in rats subjected to status epilepticus by kainate. AAPS J. 2012;14:87-96.
48. Ooie T, Terasaki T, Suzuki H, Sugiyama Y. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics. J Pharmacol Exp Ther. 1997;283:293-304.
49. Takasawa K, Terasaki T, Suzuki H, Ooie T, Sugiyama Y. Distributed model analysis of 3′-azido-3′-deoxythymidine and 2′,3′- dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J Pharmacol Exp Ther. 1997;282:1509-17.
50. Hansen DK, Scott DO, Otis KW, Lunte SM. Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. J Pharm Biomed Anal. 2002;27:945-58.
51. Bourasset F, Bernard K, Muñoz C, Genissel P, Scherrmann J. Neuropharmacokinetics of a new alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2, 4-benzothiadiazine-1,1-dioxide], in the rat. Drug Metab Dispos. 2005;33:1137-43.
52. Bourasset F, Scherrmann J-M. Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide. Life Sci. 2006;78:2302-14.
53. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS J. 2004;6:56-67.
54. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol. 2011;51:45-73.
55. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89:259-67.
56. Bouzom F, Ball K, Perdaems N, Walther B. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs? Biopharm Drug Dispos. 2012;33:55-71.
57. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, et al. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. J Pharmacol Exp Ther. 2005;313:1254-62.
58. Kielbasa W, Stratford RE. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses. Drug Metab Dispos. 2012;40:877-83.
59. Kielbasa W, Kalvass JC, Stratford R. Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab Dispos. 2009;37:137-42.
60. Westerhout J, Ploeger B, Smeets J, Danhof M, De Lange ECM. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. AAPS J. 2012;14:543-53.
61. Fenneteau F, Turgeon J, Couture L, Michaud V, Li J, Nekka F. Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. Theor Biol Med Model. 2009;6:2.
62. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G. Predicting P-glycoprotein effects on oral absorption: correlation of transport in caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004;21:819-26.
63. Pardridge WM, Triguero D, Yang J, Cancilla PA. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther. 1990;253:884-91.
64. Fenneteau F, Li J, Nekka F. Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis. J Pharmacokinet Pharmacodyn. 2009;36:495-522.
65. Nestorov IA, Aarons LJ, Rowland M. Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: a sensitivity analysis. J Pharmacokinet Biopharm. 1997;25:413-47.
66. Ball K, Bouzom F, Scherrmann J, Walther B, Declèves X. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. J Pharm Sci. 2012;101:4277-92.
67. Rostami-Hodjegan A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther. 2012;92:50-61.
68. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res. 2002;19:1400-16.
69. Ménochet K, Kenworthy KE, Houston JB, Galetin A. Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug Metab Dispos. 2012;40:1744-56.
70. Chow ECY, Pang KS. Why we need proper PBPK models to examine intestine and liver oral drug absorption. Curr Drug Metab. 2013;14:57-79.
71. Terasaki T, Ohtsuki S, Hori S, Takanaga H, Nakashima E, Hosoya K. New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov Today. 2003;8:944-54.
72. Krajcsi P, Jani M, Tóth B, Erdo F, Kis E, Beéry E, et al. Efflux transporters in the blood-brain interfaces - in vitro and in vivo methods and correlations. Expert Opin Drug Metab Toxicol. 2012;8:419-31.
73. Zhang Y, Li CSW, Ye Y, Johnson K, Poe J, Johnson S, et al. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability. Drug Metab Dispos. 2006;34:1935-43.
74. Perrière N, Yousif S, Cazaubon S, Chaverot N, Bourasset F, Cisternino S, et al. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res. 2007;1150:1-13.
75. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck M-P, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6:650-61.
76. Poller B, Gutmann H, Krähenbühl S, Weksler B, Romero I, Couraud P-O, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem. 2008;107:1358-68.
77. Shayan G, Choi YS, Shusta EV, Shuler ML, Lee KH. Murine in vitro model of the blood-brain barrier for evaluating drug transport. Eur J Pharm Sci. 2011;42:148-55.
78. Shawahna R, Decleves X, Scherrmann J-M. Hurdles with using In vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. Curr Drug Metab. 2013;14:120-36.
79. Hatherell K, Couraud P-O, Romero IA, Weksler B, Pilkington GJ. Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation transwell models. J Neurosci Methods. 2011;199:223-9.
80. Strazielle N, Ghersi-Egea J-F. In vitro models of the blood-cerebrospinal fluid barrier and their use in neurotoxicological research. Neuromethods. 2011;56:161-84.
81. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem. 2003;38:223-32.
82. Hellinger E, Veszelka S, Tóth AE, Walter F, Kittel A, Bakk ML, et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm. 2012;82:340-51.
83. Di L, Kerns EH, Bezar IF, Petusky SL, Huang Y. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J Pharm Sci. 2009;98:1980-91.
84. Tsinman O, Tsinman K, Sun N, Avdeef A. Physicochemical selectivity of the BBB microenvironment governing passive diffusion-matching with a porcine brain lipid extract artificial membrane permeability model. Pharm Res. 2011;28:337-63.
85. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, et al. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther. 2007;322:205-13.
86. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36:268-75.
87. Summerfield SG, Stevens AJ, Cutler L, Del Carmen Osuna M, Hammond B, Tang S, et al. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther. 2006;316:1282-90.
88. Lacombe O, Videau O, Chevillon D, Guyot A-C, Contreras C, Blondel S, et al. In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery. Mol Pharm. 2011;8:651-63.
89. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD, et al. In vitro models for the blood-brain barrier. Toxicol In Vitro. 2005;19:299-334.
90. Hakkarainen JJ, Jalkanen AJ, Kääriäinen TM, Keski-Rahkonen P, Venäläinen T, Hokkanen J, et al. Comparison of in vitro cell models in predicting in vivo brain entry of drugs. Int J Pharm. 2010;402:27-36.
91. Sziráki I, Erdo F, Beéry E, Molnár PM, Fazakas C, Wilhelm I, et al. Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study. J Biomol Screen. 2011;16:886-94.
92. Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, et al. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res. 2010;27:442-6.
93. Avdeef A. How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood-brain barrier permeability? Eur J Pharm Sci. 2011;43:109-24.
94. Avdeef A. Leakiness and size exclusion of paracellular channels in cultured epithelial cell monolayers-interlaboratory comparison. Pharm Res. 2010;27:480-9.
95. Avdeef A, Tam KY. How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? J Med Chem. 2010;53:3566-84.
96. Avdeef A, Artursson P, Neuhoff S, Lazorova L, Gråsjö J, Tavelin S. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method. Eur J Pharm Sci. 2005;24:333-49.
97. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos. 2008;36:2005-13.
98. Shawahna R, Uchida Y, Declèves X, Ohtsuki S, Yousif S, Dauchy S, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm. 2011;8:1332-41.
99. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci. 2011;100:3547-59.
100. Kamiie J, Ohtsuki S, Iwase R, Ohmine K, Katsukura Y, Yanai K, et al. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res. 2008;25:1469-83.
101. Ito K, Uchida Y, Ohtsuki S, Aizawa S, Kawakami H, Katsukura Y, et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci. 2011;100:3939-50.
102. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117:333-45.
103. Hoshi Y, Uchida Y, Tachikawa M, Inoue T, Ohtsuki S, Terasaki T. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J Pharm Sci. 2013. doi: 10.1002/jps.23575.
104. Uchida Y, Ohtsuki S, Kamiie J, Terasaki T. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain. J Pharmacol Exp Ther. 2011;339:579-88.
105. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl)ethyl]amino}meth. Drug Metab Dispos. 2009;37:439-42.
106. Oostendorp RL, Buckle T, Beijnen JH, Van Tellingen O, Schellens JHM. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs. 2009;27:31-40.
107. Lagas JS, Van Waterschoot RA, Van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, et al. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res. 2009;15:2344-51.
108. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, Elmquist WF. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther. 2010;334:147-55.
109. Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther. 2010;333:788-96.
110. Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther. 2011;336:223-33.
111. Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos. 2011;39:729-35.
112. Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2- (5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos. 2009;37:946-55.
113. Longhi R, Corbioli S, Fontana S, Vinco F, Braggio S, Helmdach L, et al. Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method. Drug Metab Dispos. 2011;39:312-21.
114. Fridén M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos. 2007;35:1711-9.
115. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, et al. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos. 2009;37:787-93.
116. Becker S, Liu X. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab Dispos. 2006;34:855-61.
117. Fridén M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos. 2009;37:1226-33.
118. Fridén M, Bergström F, Wan H, Rehngren M, Ahlin G, Hammarlund-Udenaes M, et al. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos. 2011;39:353-62.
119. Wan H, Rehngren M, Giordanetto F, Bergström F, Tunek A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007;50:4606-15.
120. Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, et al. Toward an improved prediction of human in vivo brain penetration. Xenobiotica. 2008;38:1518-35.
121. Di L, Umland JP, Chang G, Huang Y, Lin Z, Scott DO, et al. Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos. 2011;39:1270-7.
122. Jeffrey P, Summerfield SG. Challenges for blood-brain barrier (BBB) screening. Xenobiotica. 2007;37:1135-51.
123. Doran AC, Osgood SM, Mancuso JY, Shaffer CL. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug Metab Dispos. 2012;40:2162-73.
124. Notkina N, Dahyot-Fizelier C, Gupta AK. In vivo microdialysis in pharmacological studies of antibacterial agents in the brain. Br J Anaesth. 2012;109:155-60.
125. Syvänen S, Hammarlund-Udenaes M. Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. Curr Top Med Chem. 2010;10:1799-809.
126. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, et al. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther. 2006;317:704-10.
127. Hsiao P, Bui T, Ho RJY, Unadkat JD. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos. 2008;36:481-4.
128. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005;77:503-14.
129. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227-51.
130. Syvänen S, Lindhe O, Palner M, Kornum BR, Rahman O, Långström B, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37:635-43.
131. Zoghbi SS, Liow J-S, Yasuno F, Hong J, Tuan E, Lazarova N, et al. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J Nucl Med. 2008;49:649-56.
132. Seneca N, Zoghbi SS, Liow J-S, Kreisl W, Herscovitch P, Jenko K, et al.
133. Kreisl WC, Liow J-S, Kimura N, Seneca N, Zoghbi SS, Morse CL, et al. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med. 2010;51:559-66.
134. Sugimoto H, Hirabayashi H, Amano N, Moriwaki T. Retrospective analysis of p-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans. Drug Metab Dispos. 2013;41:683-8.
135. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang S-M, Smith QR, et al. Why clinical inhibition of efflux transport at the blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther. 2013. doi: 10.1038/clpt.2013.34.